ASH 2022 Annual Meeting – Insights Into Major Diffuse Large B-cell Lymphoma (DLBCL) Abstract and Breakthroughs
Dec 09, 2022 |
Reading Time: 2minutes
Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experiments and their upshots are always brought to us through various platforms, the American Society of Hematology (ASH) being one of them.
The 64th ASH Annual Meeting and Exposition is a four-day premier event in malignant and non-malignant hematology, scheduled to start on December 10, 2022. Like every year, the ASH conference shared new abstracts from a robust portfolio and pipeline of advanced therapeutic platforms in cancer and other blood disorders, highlighting the impact of our bold science in research. On this note, Delveinsight has listed a few major abstracts for diffuse large B-cell lymphoma (DLBCL).
The key abstracts have been summarized in the table below:
Drug regimen
Abstract ID
Abstract Title
Trial ID
Company
Class
Tafasitamab + Lenalidomide + R-CHOP
2947
Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
NCT04824092
(frontMIND)
MorphoSys AG
CD19-directed monoclonal antibody
Odronextamab
444
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
NCT03888105
(ELM-2)
Regeneron Pharmaceuticals
Bispecific antibody
Loncastuximab Tesirine + Rituximab
2955
A Phase II, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)
NCT05144009(LOTIS-9)
ADC Therapeutics
Antibody Drug Conjugate (ADC)
Epcoritamab + R-DHAX/C
443
Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase I/II Results
NCT04663347
(EPCORE NHL-2)
Genmab/AbbVie
Bispecific antibody
Mosunetuzumab
738
Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
NCT03677154
Roche
Bispecific antibody
Axicabtagene Ciloleucel + Lenzilumab
4635
ZUMA-19: A Phase I/II Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma
NCT04314843(ZUMA-19)
Gilead Sciences
CAR-T cell therapy
Iberdomide ±Anti-CD20
233
Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase I/II Study
NCT04464798
BMS
Immunomodulatory imide drug (IMiDs)
Tafasitamab + Lenalidomide + R‑CHOP
1619
First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
NCT04134936
(First-MIND)
MorphoSys AG
CD19-directed monoclonal antibody
Glofitamab + R-CHOP
737
Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study
NCT03467373
Roche
Bispecific antibody
YTB323
439
YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update
Abbvie-Genmab’s EPKINLY, the first CD20XCD3 Bispecific Antibody gets US approval for Relapsed/Refractory DLBCL treatment. Roche’s Glofitamab is expected to garner benefits in Europe first. Let's have a glimpse of evolving DLBCL treatment landscape in Relapsed/Refractory setting and if bi-specific as a class can be...
The American Society of Hematology (ASH) Annual Meeting this year presented abstracts showcasing new data from across its bispecific antibodies clinical pipeline, demonstrating the companies’ commitment to redefining care for patients with DLBCL.
Recently, off-the-shelf bispecific antibodies have grow...
American Society of Hematology (ASH) presented fresh abstracts from a strong portfolio and pipeline of cutting-edge treatment platforms for cancer and blood diseases, underscoring the significance of our audacious science in research. Delveinsight has provided a summary of some of the key abstracts and their result...
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.